Management of multiple valve disease

Unger, Philippe; Rosenhek, Raphaël; Dedobbeleer, Chantal; Berrébi, Alain; Lancellotti, Patrizio

doi:10.1136/hrt.2010.212282

Cited by 79 publications

(55 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La valvulopatía múltiple puede darse en distintas enfermedades, especialmente en las cardiopatías reumáticas y congénitas, pero también en la valvulopatía degenerativa. Debido a la falta de datos sobre las valvulopatías combinadas o múltiples, no se pueden establecer recomendaciones basadas en la evidencia 164 . Los principios generales para el tratamiento de valvulopatías combinadas o múlti-ples son los siguientes: -minante, el tratamiento debe seguir las recomendaciones sobre la valvulopatía predominante.…”

Section: Valvulopatías Combinadas Y Múltiplesunclassified

Guía ESC/EACTS 2017 sobre el tratamiento de las valvulopatías

Baumgartner¹,

Falk²,

Bax³

et al. 2018

Revista Española de Cardiología

View full text Add to dashboard Cite

Section: Valvulopatías Combinadas Y Múltiplesunclassified

Guía ESC/EACTS 2017 sobre el tratamiento de las valvulopatías

Baumgartner¹,

Falk²,

Bax³

et al. 2018

Revista Española de Cardiología

View full text Add to dashboard Cite

“…The haemodynamic consequences of MVD on blood flow, and on ventricular size, shape, and function, as well as the specific combination of valve lesions can influence the diagnostic process in many ways 10 . Physical examination can be misleading in terms of both the timing and intensity of murmurs heard during auscultation and of other signs, such as pulse pressure.…”

Section: Diagnosismentioning

confidence: 99%

“…ERO, mitral effective regurgitant orifice; MRV, mitral regurgitant volume. Adapted with permission from Unger 2011 10 . …”

Section: Figurementioning

confidence: 99%

“…Other, less frequent, causes of primary MVD include endocarditis, thoracic and mediastinal radiation therapy, and the adverse effects of drugs. Even less frequently, connective tissue disorders, aortic root and myxomatous mitral and tricuspid valve disease linked to genetic syndromes can be associated with MVD 10 . Mitral and tricuspid regurgitation can also develop in the presence of a structurally normal valve owing to malcoaptation.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Pathophysiology and management of multivalvular disease

et al. 2016

View full text Add to dashboard Cite

Multivalvular disease (MVD) is a common condition with a complex pathophysiology, dependent on the specific combination of valve lesions. Diagnosis is challenging as several echocardiographic methods commonly used for the assessment of stenosis or regurgitation have been validated only in patients with single valve disease. Decisions about the timing and type of treatment should be made by a multidisciplinary heart valve team, on a case-by-case basis. Several factors should be considered, including the severity and consequences of the MVD, the patient’s life expectancy and comorbidities, the surgical risk associated with combined valve procedures, the long-term risk of morbidity and mortality associated with multiple valve prostheses, and the likelihood and risk of reoperation. The introduction of transcatheter valve therapies into clinical practice has provided new treatment options for patients with MVD, and decision-making algorithms on how to combine surgical and percutaneous treatment options are evolving rapidly. In this Review, we discuss the pathophysiology, diagnosis, and treatment of MVD, focussing on the combination of valve pathologies that are most often encountered in clinical practice.

show abstract

“…Malfunction of the valves can be acquired or congenital and each may lead either to stenosis or regurgitation, or even both in some cases. [1] While degenerative valve disease is more common in the elderly population in industrialized countries, rheumatic valve disease is still one of the most common etiologies of valvular disease in developing countries. [2] In spite of that, the underlying mechanisms of valvular malfunction and disease progression in many acquired and congenital diseases is not yet known.…”

Section: Introductionmentioning

confidence: 99%

Animal models for heart valve research and development

Kheradvar

Zareian

Kawauchi

et al. 2017

Drug Discovery Today: Disease Models

View full text Add to dashboard Cite

Valvular heart disease is the third-most common cause of heart problems in the United States. Malfunction of the valves can be acquired or congenital and each may lead either to stenosis or regurgitation, or even both in some cases. Heart valve disease is a progressive disease, which is irreversible and may be fatal if left untreated. Pharmacological agents cannot currently prevent valvular calcification or help repair damaged valves, as valve tissue is unable to regenerate spontaneously. Thus, heart valve replacement/repair is the only current available treatment. Heart valve research and development is currently focused on two parallel paths; first, research that aims to understand the underlying mechanisms for heart valve disease to emerge with an ultimate goal to devise medical treatment; and second, efforts to develop repair and replacement options for a diseased valve. Studies that focus on developmental malformation, genetic and disease epigenetics usually employ small animal models that are easy to access for in vivo imaging that minimally disturbs their environment during early stages of development. Alternatively, studies that aim to develop novel device for replacement and repair of diseased valves often employ large animals whose heart size and anatomy closely replicate human’s. This paper aims to briefly review the current state-of-the-art animal models, and justification to use an animal model for a particular heart valve related project.

show abstract

Management of multiple valve disease

Cited by 79 publications

References 46 publications

Guía ESC/EACTS 2017 sobre el tratamiento de las valvulopatías

Guía ESC/EACTS 2017 sobre el tratamiento de las valvulopatías

Pathophysiology and management of multivalvular disease

Animal models for heart valve research and development

Contact Info

Product

Resources

About